Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma

Journal of Drugs in Dermatology

Volumn 9, Issue 2, 2010, Pages 169-171

  Diamantis, Melissa L ^a   Chon, Susan Y ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; SORAFENIB; TRIAMCINOLONE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CHEMOSURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; EPIDERMIS HYPERPLASIA; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HUMAN; HYPOTHYROIDISM; LUNG METASTASIS; MALE; METASTATIC THYROID CARCINOMA; PARAKERATOSIS; PSORIASIS; PUNCH BIOPSY; SKIN CARCINOMA; SKIN EXAMINATION; SQUAMOUS CELL CARCINOMA; THYROID CARCINOMA; TRACHEOESOPHAGEAL FISTULA; CHEMICALLY INDUCED DISORDER; METASTASIS; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIDINES; THYROID NEOPLASMS;

EID: 77949894522     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
2. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574. (Pubitemid 46295136)
3. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326-334. (Pubitemid 43338212)
4. Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 2009;61:360-361.
5. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045-1051.
6. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144:886-892. (Pubitemid 352039741)
7. Maddox JS, Kung EF, Petronic-Rosic V, Sethi A. Cutaneous drug eruptions induced by sorafenib: A case series. J Drugs Dermatol. 2008;7:891-893.
8. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2007;56:171-172.
9. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7:20-23.
10. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006;31:783-785. (Pubitemid 44563396)
11. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008;111:5610-5620.
12. Jost M, Kari C, Rodeck U. The EGF receptor: An essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10:505-510.
13. Galan Brotons A, Borras-Blasco J, Rosique-Robles JD, et al. Generalised erythematous skin eruptions induced by sorafenib: Cutaneous toxicity and treatment outcome. Clin Transl Oncol. 2008;10:844-846.